King's College London

King's Research Portal

Link to publication record in King's Research Portal

Citation for published version (APA):
Salazar de Pablo, G., Aymerich, C., Guinart, D., Catalan, A., Alameda, L., Trotta, G., Armendariz, A., Baringo, E. M., Soler-Vidal, J., Rubio, J. M., Garrido-Torres, N., Gomez Vallejo, S., Kane, J. M., Howes, O., Fusar-Poli, P., & Correll, C. U. (in press). What is the duration of untreated psychosis worldwide? - A meta-analysis of pooled mean and median time and regional trends and other correlates across 369 studies. *Psychological medicine*.

Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal

Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 12. Jan. 2025

WHAT IS THE DURATION OF UNTREATED PSYCHOSIS WORLDWIDE?

- A META-ANALYSIS OF POOLED MEAN AND MEDIAN TIME AND REGIONAL TRENDS AND OTHER CORRELATES ACROSS 369 STUDIES

Study Team

Gonzalo Salazar de Pablo[1,2,3,4,], Claudia Aymerich[5], Daniel Guinart[6,7,8,9], Ana Catalan[2,5], Luis Alameda[10,11,12]; Giulia Trotta[10], Alvaro Armendariz[13], Estrella Martinez Baringo[13], Joan Soler-Vidal[14,15,16], Jose M Rubio[6,7,8], Nathalia Garrido-Torres[12], Sandra Gómez Vallejo[17], John M. Kane[6,7,8], Oliver Howes[10,18], Paolo Fusar-Poli[2,19,20,21], Christoph U. Correll, MD[6,7,8,22]

Affiliations:

[1]Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK;
[2]Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK;
[3]Child and Adolescent Mental Health Services, South London and Maudsley NHS Foundation Trust, London, UK;
[4]Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health. Hospital General Universitario Gregorio Marañón School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain;
[5]Psychiatry Department. Basurto University Hospital. Biocruces Bizkaia Health Research Institute. OSI Bilbao-Basurto, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) Barakaldo, Bizkaia, Spain;
[6]The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA;
[7]Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/ Northwell, Hempstead, NY, USA;
[8]Institute of Behavioral Science; The Feinstein Institutes for Medical Research, Manhasset, NY, USA;
[9]Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Institut de Neuropsiquiatria i Addiccions (INAD), Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) Barcelona, Spain;
[10]Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;
[11]TiPP Program Department of Psychiatry, Service of General Psychiatry, Lausanne University Hospital, Lausanne, Switzerland;
[12] University Hospital Virgen del Rocio-IBIS Sevilla ,CIBERSAM, ISCIII Spanish Network for Research in Mental Health, Sevilla, Spain;
[9]Department of Psychiatry, Faculty of Medicine, Université Paris Cité, Paris, France;
[13]Department of Psychiatry and Psychology, Hospital Sant Joan de Déu de Barcelona, L'Hospitalet de Llobregat, Spain;
[14] FIDMAG Germanas Hospitalàries Research Foundation, Barcelona, Spain;
[15]Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Spain;
[16]Hospital Benito Menni CASM, Hermanas Hospitalarias, Sant Boi de Llobregat, Spain;
[17]Child and Adolescent Psychiatry and Psychology Department, Institute of Neurosciences, Hospital Clínic, Barcelona, Spain;
[18]Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom.
[19]Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy;
[20]OASIS service, South London and Maudsley NHS Foundation Trust, London, UK;
[21]National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.;
[22]Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.

Number of words text: 4756 words

Number abstract: 250 words

Number of tables: 3

Number of figures: 2

Number of supplementary tables: 6

Number of supplementary texts: 2

Correspondence to: Gonzalo Salazar de Pablo, MD, PhD; Department of Child and Adolescent Psychiatry Institute of Psychiatry, Psychology & Neuroscience (IoPPN) King's College London 16 De Crespigny Park, London SE5 8AB Tel: 0207 848 0002

ABSTRACT

Duration of untreated psychosis (DUP) has been associated with poor mental health outcomes. We aimed to meta-analytically estimate the mean and median DUP worldwide, evaluating also the influence of several moderating factors. This PRISMA/MOOSE-compliant meta-analysis searched for non-overlapping individual studies from inception until 9/12/2022, reporting mean±SD or median DUP in patients with first episode psychosis (FEP), without language restrictions. We conducted random-effect meta-analyses, stratified analyses, heterogeneity analyses, meta-regression analyses and quality assessment (PROSPERO:CRD42020163640). From 12,461 citations, 369 studies were included. The mean DUP was 42.6 weeks (95% confidence interval (CI)=40.6-44.6, k=283, n=41,320), varying significantly across continents ($p<0.001$). DUP was (in descending order) 70.0 weeks (95%CI=51.6-88.4, k=11, n=1,508) in Africa; 48.8 weeks (95%CI=43.8-53.9, k=73, n=12,223) in Asia; 48.7 weeks (95%CI=43.0-54.4, k=36, n=5,838) in North America; 38.6 weeks (95%CI=36.0-41.3, k=145, n=19,389) in Europe; 34.9 weeks (95%CI=23.0-46.9, k=11, n=1,159) in South America and 28.0 weeks (95%CI=20.9-35.0, k=6, n=1,203) in Australasia. There were differences depending on the income of countries: DUP was 48.4 weeks (95%CI=43.0-48.4, k=58, n=5,635) in middle-low income countries and 41.2 weeks (95%CI=39.0-43.4, k=222, n=35,685) in high income countries. Longer DUP was significantly associated with older age ($\beta=0.836$, $p<0.001$), older publication year ($\beta=0.404$, $p=0.038$) and higher proportion of non-White FEP patients ($\beta=0.232$, $p<0.001$). Median DUP was 14 weeks (Interquartile range=8.8-28.0, k=206, n=37,215). In conclusion, DUP is high throughout the world, with marked variation. Efforts to identify and intervene sooner in patients with FEP, and to promote global mental health and access to early intervention services (EIS) are critical, especially in developing countries.

Keywords: Duration of untreated psychosis, First Episode Psychosis, Early intervention, Meta-analysis.

INTRODUCTION

Duration of untreated psychosis (DUP) is usually defined as the period between the onset of psychosis and the start of treatment for psychosis (Hegelstad et al. 2012), although other definitions have been considered (Compton et al. 2007; Golay et al. 2016). DUP has been extensively studied as a prognostic factor in psychotic disorders like schizophrenia, and longer DUP has been associated with poorer outcomes (Oliver et al. 2018b; Penttila et al. 2014). According to a recent umbrella review on prognostic outcomes, there is highly suggestive evidence for a relationship between longer DUP and more severe positive symptoms, negative symptoms and lower chances of remission (Howes et al. 2021). Furthermore, there is suggestive evidence for an association between longer DUP and both poorer overall functioning and more severe global psychopathology (Howes et al. 2021).

Reducing DUP through public awareness, training and improving treatment access should be a major goal of early intervention programs (Malla et al. 2021). The World Health Organization and the International Early Psychosis Association produced a consensus statement fifteen years ago. These organizations recommended active efforts to reduce mean DUP to less than three months in individuals with a first episode of psychosis (FEP) (Bertolote et al. 2005). However, previous evidence has reported mean DUPs way over this threshold (61.3 weeks, k=33 studies, non-metanalytical evidence) (Penttila et al. 2014). The DUP distribution is usually right-skewed, as there are some individuals with very long DUP, which are challenging to detect and engage in treatment with current strategies (Johannessen et al. 2001). Thus, the median DUP is generally lower than the mean DUP (12 weeks, according to evidence from 28 studies) (Boonstra et al. 2012). Currently, the efficacy of interventions to reduce DUP is limited (Oliver et al. 2018a). It is further insufficiently clear, which factors result in a longer or a shorter DUP, including variations across different continents, which may be related to different pathways to care, including the availability and use of early intervention services (EIS). Moreover, multiple demographic factors can influence DUP, and a better understanding of the relationship between such factors and DUP is critical to inform resource planning and allocation that would improve strategies to detect and treat patients early in the course of their psychotic illness.

While a recent meta-analysis estimated the association between DUP and outcomes both at baseline and follow-up (Howes et al. 2021), to the best of our knowledge, no study has quantified meta-analytically the duration of untreated psychosis and its correlates. A plethora of studies reporting on the duration of DUP and potential correlates have been published, making an evaluation of the DUP characteristics and correlates worldwide essential, particularly to review if and where the desired or even targeted reduction of DUP

has been achieved. Thus, the aim of this study was to meta-analytically evaluate the mean and median DUP worldwide and in each continent, evaluating also for the first time a wide range of factors that may moderate DUP.

METHODS

This meta-analysis (PROSPERO:CRD42020163640) was conducted in accordance with the guidelines of the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA, eTable I) (Moher et al. 2009) and the "Meta-analyses Of Observational Studies in Epidemiology" (Moose) checklist (eTable II) (Stroup et al. 2000).

Search strategy and selection criteria

A systematic search strategy was used to identify relevant articles, and independent researchers implemented a two-step literature search. The following search terms were applied: ("schizophrenia" OR "schizoaffective" OR "schizophreniform" OR "psychosis" OR "psychotic") AND ("first episode" OR "early episode" OR "early phase" OR "first break" OR "duration untreated psychosis"). First, independent researchers conducted the electronic search in PubMed, PsychInfo, SciElo Citation Index and KCI Korean Journal databases from inception until November-1-2020, without restrictions on language. The literature search was subsequently updated up to December-08-2022. Titles and abstracts of articles identified were screened, and after the exclusion of those which did not meet our inclusion criteria, the full texts of the remaining articles were assessed for eligibility. Then, final decisions were made regarding their inclusion in the review by consensus or remediation by the first and/or last author. We completed our search by manually reviewing the references of the included articles. The following inclusion criteria were used to select the articles: a) individual studies, b) conducted in FEP, either with affective psychosis, non-affective psychosis or both, c) reporting either mean±SD DUP and/or median DUP (see eMethods I for DUP operationalization), d) in any language, and e) without restrictions on sex, age, or ethnicity. Exclusion criteria were the following: a) reviews, clinical cases, abstracts and study protocols, b) studies reporting DUP using other measures or evaluating DUP categorically (i.e., not reporting mean±SD or median DUP), c) overlapping studies as defined by study program and recruitment period as well as >/=50% overlap in recruitment periods (>50 authors were contacted for missing data or clarify overlap).

Outcome measures and data extraction

Data were independently extracted by consultant psychiatrists/ senior clinical academics. Any discrepancies were resolved through consensus meetings, or consulting the first and/or last authors. The variables extracted included: first author and year of publication, country, design (cross-sectional vs. longitudinal vs. clinical trial), sample size, mean age, sex (% males), FEP diagnosis (structured vs. clinical), DUP definition (see eMethods I and operationalization below), substance use disorders (included vs. excluded), affective psychosis (included vs. excluded, and % affective psychosis), % white race, % single, % married, % living alone, main outcome (mean±SD DUP, median DUP or both, in weeks), and quality (see below).

Operationalization duration of untreated psychosis

DUP is typically operationalized as the period between the onset of psychotic symptoms and the initiation of intervention (Howes et al. 2021). The initiation of intervention may be defined according to the establishment of the first antipsychotic medication (Rizos et al. 2010), the first contact with a mental health care provider (Johnstone et al. 1986) or the first hospitalization (Jonas et al. 2020). Other definitions have been piloted. Some studies use instead of the first psychotic symptom the first psychiatric symptom (Compton et al. 2007), the first changes in behaviour (Marchira et al. 2016) or the prodromal period (Beiser et al. 1993) as the starting point. The first effective treatment (Polari et al. 2011) and the first treatment for which adherence has been achieved (Casey et al. 2016) have been used as an alternative end point of DUP. Different instruments have been considered to operationalize DUP, including the "Circumstances of Onset and Relapse Schedule" (CORS) (Malla et al. 2006); the "Interview for the Retrospective Assessment of the Onset of Schizophrenia" (IRAOS) (Häfner et al. 1992); the "Nottingham Onset Schedule" (NOS) (Singh et al. 2005); and the "Beiser scale" (Beiser et al. 1993).

Strategy for data synthesis

We first provided a quantitative summary of the DUP worldwide for studies providing mean± SD (in weeks), which was the primary outcome of this meta-analysis. Data from studies providing DUP values in another time measure (i.e., days/months/years) were converted to weeks. When mean±SD DUP was reported for the subgroups only (i.e., when the results for the total FEP were unavailable), subgroup information was combined weighted by sample size, using a calculator developed in an excel file. Furthermore, we extracted the

median, interquartile range (IQR) and range of the DUP for the studies reporting median DUP. When the studies reported median DUP for the subgroups only, and when overall results from the authors to see the distribution of the whole sample could not be obtained, data from the subgroups were introduced independently since it was not possible to precisely estimate the overall median DUP without knowing the data distribution.

Since high heterogeneity was expected, random-effects meta-analyses were conducted (DerSimonian et al. 1986). Heterogeneity among study point estimates was assessed using the Q statistics and Tau^2. The proportion of the total variability in the effect size estimates was evaluated with the I^2 index (i.e., I^2 <50%: non-significant heterogeneity, I^2 ≥50-74%: moderate heterogeneity, I^2 ≥75%: marked heterogeneity) (Lipsey et al. 2000). Publication bias was assessed by visually inspecting the funnel plot and by conducting Egger's test (Egger et al. 1997). Prediction intervals were further calculated.

Multiple sub-analyses were conducted for both mean and median DUP. Stratified DUP was estimated when three or more studies were available per predefined subgroup. Sensitivity analysis included stratified mean and median DUP results according to (i) publication decade (1991-2000 vs. 2001-2010 vs. 2011-2020 vs 2021-2022), (ii) study continent (Europe vs. Asia vs. Africa vs. North America vs. South America vs. Australasia), (iii) income level (high income countries vs middle-low income countries) (as defined by the World Bank country classifications by income level (2022-2023)) (iv) FEP diagnosis (structured vs. clinical), (v) DUP definition (from first psychotic symptom to antipsychotic treatment intervention vs other definitions, see eMethods I), (vi) exclusion vs. lack of exclusion of FEP with substance use disorders, (vii) samples with only non-affective psychosis vs. samples where FEP with affective psychosis were included, (viii) exclusion long DUP (DUP over a threshold -as per author's definition- excluded vs long DUP not excluded/ not mentioned) and (ix) setting (samples from FEP programs vs others). Sensitivity analyses according to publication decade by study continent for those continents with enough number of studies (Europe, Asia, North America) were also carried out. Sensitivity analyses for countries with at least 10 independent samples were carried out.

To compare subgroups for the median DUP, since a meta-analysis would not accurately reflect the distribution of the differences in medians, non-parametric individual analyses (Kruskal-Wallis) were used to evaluate subgroup differences using https://www.socscistatistics.com/tests/kruskal/default.aspx, and H statistic and p-values were provided. Finally, for the studies providing both mean±SD and median±IQR DUP metrics, a meta-analysis was conducted to directly compare mean and median DUP values

from in the same population assessed with the same definition of DUP. For this analysis, the width of the interquartile range was considered as 1.35 SDs(https://handbook-5-1.cochrane.org/chapter_7/7_7_3_5_mediansand_interquartile_ranges.htm), following Cochrane's guidelines. These two last sensitivity analyses were not part of the initial protocol.

Furthermore, we conducted meta-analytic regression analyses for our primary outcome (mean DUP) whenever ten or more studies were available (Cumpston et al. 2019) to estimate the association between the mean DUP and the (i) % with affective psychosis, (ii) mean age, (iii) sex (% males), (iv) sample size, (v) year of publication, (vi) % white race, (vii) % single, (viii) % married, (ix) % living alone, and (x) quality of the study (total NOS score). https://mapchart.net/world-advanced.html was used to create a figure with the countries in which DUP was reported in at least one of the included studies. Comprehensive Meta-analysis (CMA) V3 (Borenstein et al. 2013) and Stata statistical software version 16 (StataCorp) (Nyaga et al. 2014) were used to perform the analyses that were all two-sided and with alpha=0.05.

Risk of bias (quality) assessment

Study quality was assessed using items from the Newcastle-Ottawa Scale for cohort studies (Wells et al. 2014). A score of 0-9 was reported based on representativeness, selection of the cohorts, ascertainment of exposure, outcome of interest, comparability of cohorts, assessment of outcomes, and duration/adequacy of follow-up (see eMethods II).

RESULTS

Sample characteristics

The literature search yielded 12,461 citations, which were screened for eligibility, 3,359 full-text articles were assessed and 369 studies were included in the meta-analysis (Figure 1): 283 studies reporting mean±SD DUP and 206 reporting median DUP (i.e., some studies reported only mean±SD or median DUP while others reported both measures). The database included 57,715 FEP individuals. The sample size ranged from 7 to 1,724 FEP individuals (eTable III). The mean age was 26.1±4.5 and ranged 14.7-45.5 years. The proportion of males in the included studies was 62.0% and the years of education 11.2±3.0. Altogether, 43.7% were white, 75.4% were single, 17.2% were married, and 22.8% were living alone (eTable III).

Quality assessment

Study quality scores ranged from 3 to 9 (eTable III). The overall mean quality score of the included studies was 6.6±1.4.

Duration of Untreated Psychosis worldwide and by continents

The pooled mean DUP was 42.6 weeks (95%CI=40.6-44.6, k=283;n=41,320). Differences were found between the studies according to the continent in which the study was carried out (Q=42.7 p<0.001). DUP ranged (in descending order) from 70.0 weeks (95%CI=51.6-88.4, k=11;n=1,508) in Africa; 48.8 weeks (95%CI=43.8-53.9, k=73;n=12,223) in Asia; 48.7 weeks (95%CI=43.0-54.4, k=36;n=5,838) in North America; 38.6 weeks (95%CI=36.0-41.3, k=145;n=19,389) in Europe; 34.9 weeks (95%CI=23.0-46.9, k=11;n=1,159) in South America and to 28.0 weeks (95%CI=20.9-35.0, k=6;n=1,203) in Australasia (Table 1, eTable IV-A). In Europe, mean DUP ranged from 88.0 weeks (95%CI=18.5-157.6) in the 1991-2000 decade; 39.0 weeks (95%CI=34.4-43.6) in the 2001-2010 decade, 42.5 weeks (95%CI=38.6-46.4) in the 2011-2020 decade, and to 23.8 weeks (95%CI=18.2-29.3) in the 2021-2022 decade, with differences according to the publication decade being statistically significant in Europe (Q=32.3 p=<0.001), but not the other continents with sufficient data (Asia: p=0.574; North America: p=0.524) (eTable IV-B).

The pooled median DUP was 14 weeks [Interquartile range (IQR)=8.8-28.0, k=206;n=37,215]: DUP in the studies conducted in different continents varied (H=9.5, p=0.049), ranging (in descending order) from 22.5 weeks in Africa (IQR=6.0-47.7, k=10;n=1,211); 20.8 weeks in North America (IQR=9.1-35, k=37;n=7,390); 17.1 weeks in Asia (IQR=12-28.9, k=43;n=8,689); 12.0 weeks in Europe (IQR=8.2-27, k=102;n=16,500); 10 weeks in South America (IQR=8.7-14, k=6;n=1,055) and to 8 weeks in Australasia (IQR=6.0-13.0, k=8;n=2,370). No other subgroup differences were found according to the continent where the study was conducted, FEP diagnosis or exclusion of substance use disorders or affective psychosis (Table 2, eTable V).

Stratified analysis of Duration of Untreated Psychosis

The mean DUP ranged between 58.5 weeks (95%CI=33.4-83.5; k=5;n=286) in the 1991-2000 decade; 42.8 weeks (95%CI=39.1-46.6; k=62;n=8,889) in the 2001-2010 decade, 44.5 weeks (95%CI=41.6-47.4; k=169;n=25,835) in the 2011-2020 decade, and 35.4 weeks (95%CI=31.1-39.7; k=47;n=6,664) in the 2021-2022 decade, with significant differences across decades (Q=13.9p=0.003 eTable IV-A). DUP differed depending on the income level of countries where the studies were conducted, with longer DUP in middle-low than in high-income countries (48.4 weeks, 95%CI=43.0-48.4; k=58;n=5,635 vs 41.2

weeks, 95%CI=39.0-43.4; k=222;n=35,685), Q=5.8, p=0.016). DUP was shorter in studies excluding individuals with DUP over a threshold (23.4 weeks, 95%CI=11.9-35.6; k=7, n=920) compared to those not excluding them (43.0 weeks, 95%CI=40.9-45.0; k=276, n=40,757) (Q=13.8, p=0.001). The median DUP ranged between 16 weeks (IQR=8.0-18, k=6;n=541) in the 1991-2000 decade; 13 weeks (IQR=8.4-26, k=63;n=11,383) in the 2001-2010 decade; 15.5 weeks (IQR=8.7-32.7, k=130;n=24,662) in the 2011-2020 decade; and 11 weeks (IQR=8.6-21.7, k=7;n=629) in the 2021-2022 decade (eTable V).

The meta-analytic mean and median DUP for the 43 independent studies providing both metrics was 44.2 weeks (95%CI=39.4-49.0) for mean DUP and 17.4 weeks (95%CI=14.5-20.3) for median DUP. Among the countries with at least ten studies available, mean DUP ranged from 27.5 weeks in Spain (95%CI=22.0-33.0, k=23;n=3,063) to 50.6 weeks in Japan (95%CI=40.8-60.4, k=17;n=1,447).

Studies in which FEP with affective psychosis were excluded had a higher mean DUP (46.7 weeks, 95%CI=44.0-49.4, k=168;n=18,212) compared to studies including individuals with affective psychosis (37.7 weeks, 95%CI=34.2-41.1, k=96;n=18,086) (Q=16.7, p<0.001). No differences in DUP were found according to the DUP definition, the exclusion of FEP with substance use disorders, the use of structured or clinical instruments to diagnose FEP or the setting (all p>0.05) (eTable IV-A). Stratified analyses for median DUP can be seen at eTable V.

Heterogeneity and publication bias assessment

Heterogeneity was marked for the primary analysis evaluating mean DUP (I2=97.8%, Q=12713.3, p<0.001, Tau^2=229.2), as well as for the stratified analysis by study continent (I2=88.1-98.2%, Q=83.9-7085.5, Tau^2=94.4-832.8, all p<0.001). Publication bias was not identified.

Meta-regression analyses

Longer DUP was associated with older mean patient age (β=0.836, p<0.001), older year of publication (β=0.404, p=0.038) and higher proportion of non-White FEP patients (β=0.232, p<0.001)(Table 3). No significant associations were found between DUP and the % of affective psychosis, sample size, % of males, % of single/married individuals, % of those living alone or quality of the studies (all p>0.05).

DISCUSSION

To our knowledge, with 359 studies (283 studies reporting mean±SD DUP; 206 reporting median DUP) and 57,715 FEP individuals, this is the largest meta-analysis to summarize the mean and median DUP worldwide. We further evaluated comprehensively, for the first time, the influence of a broad range of moderating factors through our stratified subgroup and meta-regression analyses.

The pooled mean DUP was 42.6 weeks (95%CI=40.6-44.6) and the pooled median DUP was 14 weeks (IQR=8.8-28.0) in FEP individuals. Thus, the recommendations established over 15 years ago of reducing mean DUP to less than 3 months in individuals with a FEP (Bertolote et al. 2005) have not been implemented successfully with the current strategies. The 300% longer mean DUP than median DUP indicates that a significant subgroup of patients has a very long DUP, right-skewing the results of the mean. Information about this subgroup and how to reach and engage these FEP patients in treatment earlier is at least as important as reducing the DUP in all individuals where it is longer than 3 months. Future studies should report DUP and characteristics by group tertiles, quartiles or quintiles (depending on sample size) to advance the discussion about targeted interventions to reduce the DUP and whether a reduction in DUP would improve outcomes.

Differences in DUP duration were observed according to the publication decade - although not for median DUP -, indicating some overall reduction in the mean DUP worldwide over time and compared to previous evidence from the first 33 published studies (42.6 vs 61.3 weeks (Penttila et al. 2014)). However, the pooled median DUP remained somewhat higher than the previous meta-analytically pooled evidence (14 vs 12 weeks (Boonstra et al. 2012)). The most likely interpretation is that there are still individuals with very long DUP who are challenging to detect and thus are less likely to receive appropriate early interventions at the moment (Johannessen et al. 2001). Unsurprisingly, in our sub-analyses, when authors excluded individuals with long DUP from their studies, the DUP decreased, which supports this hypothesis. In any case, delays in access to clinical care/ appropriate care have remained frequent, which highlights an urgent need to improve current early intervention strategies for those individuals with FEP who are particularly difficult to detect early in their course of their psychotic illness (Lloyd-Evans et al. 2011; Perkins et al. 2005).

The DUP varied across continents, and some continents were more represented than others in this meta-analysis. At the same time, the DUP from some regions and countries has never been reported or at least published in peer-reviewed journals (see Figure 2). DUP was almost triple in Africa (mean DUP=70.0 weeks, median DUP=22.5 weeks) than in Australia (mean DUP=28.0 weeks, median DUP=8 weeks); a possible explanation for this is a lack of resources, particularly for early intervention across most of Africa, contrasted by

the publicly-funded presence of a longstanding tradition to implement EIS in Australia (Malla et al. 2019) where mean and median DUP was lower than on any other continent. Thus, these results suggest that countries such as Australia, pioneering the EIS programs, have been able to manage the earlier detection and treatment of patients with FEP more successfully than other regions in the world that should learn from the Australian model, supported by public funding. Equally DUP was longer in middle-low income countries compared to high income countries.

In our meta-regression analyses, White ethnicity was associated with shorter DUP, which is worrying, as it highlights difficulties to access clinical services by ethnic minorities. Furthermore, this finding suggests that differential pathways to care may not only exist across different geographical locations but also within the same region, and that social determinants of heath, including elements of culture, health literacy, stigma, social stress and exclusion, health access and inequality require focused attention (Filia et al. 2022; Guinart et al. 2019; Rice et al. 2018; Salazar de Pablo et al. 2020). In fact, within the same population in Canada, the median DUP was more than double in Black-Caribbean individuals than in White-Europeans (Anderson et al. 2015). Furthermore, rates of schizophrenia were found to be higher in Black Caribbean (RR: 5.6), Black African (RR: 4.7) and South Asian individuals (RR: 2.4) compared to White British individuals in the UK (Kirkbride et al. 2012). Black, Asian, mixed, and other ethnicities have been associated with an increased risk of developing psychosis relative to White ethnicity, and are used in risk calculators to predict psychosis onset (Fusar-PoliRutigliano et al. 2017). Our results highlight the importance of launching culturally sensitive global health and global mental health programs and campaigns to better detect the specific needs and to identify and treat ethnic minority groups earlier. Global health intends to improve health and achieve equity in health for all people worldwide (Koplan et al. 2009; Patel et al. 2010). Global mental health and promotion of mental health to achieve the same goals are equally important (Salazar de Pablo et al. 2020). However, significant barriers to service delivery in global mental health exist, including lack of culturally appropriate screening tools and interventions and human resources trained to deliver the necessary care (Qureshi et al. 2021). Future research and health governance should advance by developing culturally sensitive approaches (Snodgrass et al. 2017).

EIS typically provide treatment and support for both individuals experiencing psychosis and individuals who are at clinical high-risk of developing psychosis (CHR-P) (NHS-England The National Collaborating Centre for Mental Health and the National Institute for Health and Care Excellence 2016). The CHR-P paradigm originated in Australia 25 years ago

(Yung et al. 2005). Australia is known for its mental health initiatives for young people (Rickwood et al. 2019), including their CHR-P and early intervention services, which according to our results appear to have been more capable than other regions to yield a lower DUP. Implementing CHR-P services have been considered the most effective method for lowering DUP (Oliver et al. 2018a), since individuals can receive preventive interventions before they transition to psychosis. Furthermore, the detection of individuals at CHR-P (Fusar-Poli et al. 2019) and the development and implementation of preventive interventions (Fusar-Poli et al. 2020) can maximize the benefits of early intervention in people at risk for and with psychosis (Correll et al. 2018b; Fusar-PoliMcGorry et al. 2017). However, currently, only a small proportion of individuals with manifest FEP had been previously seen at CHR-P services (Ajnakina et al. 2017). Therefore, additional strategies to reduce DUP effectively both across patients with FEP and within subgroups of greatest need to reduce the DUP are needed. So far, we did not detect a reduction in DUP in those studies reporting results from a FEP program compared to other studies. It may also be that our statistical power was limited (K=35 studies in the FEP group). In any case, meta-analytical evidence from randomized clinical trials may be able to better clarify whether FEP services focusing on DUP result in a decrease in DUP.

According to our meta-regression analyses, besides a larger proportion of non-White individuals, discussed above, a higher mean age was also associated with a longer DUP. One hypothesis why higher mean age might be associated with longer DUP is that it may be particularly challenging for older individuals to access clinical care (Mikton et al. 2021). Most early intervention services for FEP only accept patients until 35 years (Grawe et al. 2006) or 40 years (Kane et al. 2016). Furthermore, 85.7% of CHR-P services only accept individuals until 35 years (Salazar de Pablo et al. 2021), and some have even younger thresholds (Tiffin et al. 2007) or only accept individuals within 2 years of psychosis onset (Dixon et al. 2018). The age of onset may also be similar and the older age in individuals with longer DUP may be an artifact or a consequence of DUP per se. These considerations may suggest age and gender-sensitive approaches in early psychosis programs (Sommer et al. 2020). Additionally, younger individuals with FEP may still be embedded and engage in more social contexts, which may increase surveillance and identification of problems, leading to the initiation of mental help seeking behaviors.

Interventions to reduce DUP based on early detection and intervention have been developed in FEP (Correll et al. 2018b; Lieberman et al. 2019). A previous meta-analysis found that early intervention services were superior to treatment as usual on a wide range of clinical and functional outcomes (Correll et al. 2018a). Benefits of early intervention

services may include a decrease of suicide attempts (Chan et al. 2018; Melle et al. 2010) and an increase of service users' satisfaction as well (Cullberg et al. 2002). From a management perspective, the costs of early intervention services are lower than the control group costs (Mihalopoulos et al. 2009), particularly due to lower inpatient costs (Cullberg et al. 2006). Unfortunately, the capacity of EIS for reducing DUP has been limited(Oliver et al. 2018a). There is still a significant subgroup of individuals with very long DUP (Johannessen et al. 2001), that can only reach care with intensive efforts from professionals and outreach strategies (Lynch et al. 2016) including information campaigns (Joa et al. 2008) as well as social media and digital approaches (Birnbaum et al. 2017; Birnbaum et al. 2018). Barriers to early detection include difficulties to detect signs of early psychosis (Lloyd-Evans et al. 2015), worries about stigma or coercive treatment (Lloyd-Evans et al. 2015), and family difficulties (Qiu et al. 2019). The influence of other clinical and social factors should be considered and addressed. For instance, meta-analytic evidence found a significant association between cannabis use and a 2.7 years earlier age at the onset of psychosis (Large et al. 2011), which is a relevant consideration given the multinational developments towards legalization of cannabis use (Pearson 2019).

The current study has several limitations. First, despite the large overall database, the number of studies was limited for some of the subgroups. For instance, the number of studies providing data on DUP in Africa, South America or Australia was more limited than the number of studies providing DUP results in Europe or Asia, and there was no information available for some countries. Furthermore, there were only five studies published in the 1991-2000 decade, in part because some of the cohorts and programs established in that decade published more extensive but significantly overlapping results in later years, which we had to exclude to avoid double-counting. However, the database was large and sufficiently powered to test our hypothesis. Second, heterogeneity was significant for DUP, and thus prediction intervals are broad. Different factors may have influenced the results. We conducted additional meta-regression and subgroup analyses to evaluate the influence of some of these factors. This heterogeneity of the results is common in real-world scenarios, which may have helped us obtain a broader, more realistic picture of the current state of the field. Third, the definitions of DUP were heterogeneous, and 148 studies (40%) did not provide a definition for DUP. Lack of differences in DUP results depending on the definition may have been influenced by this lack of information or lack of statistical power. Alternatively, variations in DUP due to differences in its definition may simply be too small compared to the many other, more powerful factors prolonging DUP. Fourth, only 6.5% of FEP individuals had affective psychosis, while higher proportions have been reported in the literature. Future research should disentangle the peculiarities of individuals with affective

psychosis regarding DUP compared to individuals with non-affective psychosis. Fifth, the observed correlation between older age and longer DUP could well be due to the correlated nature of the two variables. Future studies should explore the correlations within birth/age cohorts, ideally using individual level data, in order to better examine this feature. Sixth, the results for the median DUP were not meta-analytical but calculated based on the distributions as advised by expert statisticians. Finally, we did not evaluate the impact of DUP or its consistency as a prognostic factor for the illness trajectory or as a predictive factor for either the effect of the clinical interventions to reduce DUP or for DUP as a moderator of treatment for FEP. These topics have previously been addressed elsewhere (Howes et al. 2021) and will need to be reviewed periodically in future studies and meta-analyses.

In conclusion, DUP remains problematically high throughout the world, and particularly so in some less developed continents. Although mean DUP has been reducing globally, it remains longer than recommendations, even in regions with a strong public health focus on early identification and intervention. This highlights the need for further efforts to intervene sooner and to promote global mental health and access to early intervention, particularly in developing countries. EIS should pay greater attention to the earlier and culturally sensitive detection and intervention of ethnic minority groups, and limiting the age or illness duration as criteria for inclusion might need to be reconsidered, given the particularly long DUP in older individuals who will otherwise be excluded albeit requiring increased attention.

Declaration of interest: Dr Salazar de Pablo has received honoraria from Janssen Cilag and Menarini. Dr Aymerich has received honoraria from Neuraxpharm. Dr. Guinart has been a consultant for and/or has received speaker honoraria from Otsuka America Pharmaceuticals, Janssen Pharmaceuticals, Lundbeck and Teva. Dr Rubio has received consulting fees from TEVA, Janssen and Karuna, research support from Alkermes, royalties from UpToDate. Prof Howes is a part-time employee and stock holder of Lundbeck A/s. He has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organised by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Recordati, Roche and Viatris/ Mylan. Dr Howes has a patent for the use of dopaminergic imaging. Dr. Kane has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Biogen, Boehringer-Ingelheim, Cerevel, Click, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, Merck, Neurocrine, Newron, Otsuka, Reviva, Saladax, Sunovion and Teva. He has received grant support from Lundbeck, Otsuka, Janssen and Sunovion. He is a shareholder of HealthRhythms, LB

Pharma, Medincell and The Vanguard Research Group. Dr Fusar-Poli has received research fees from Lundbeck and honoraria from Lundbeck, Angelini, Menarini and Boehringer Ingelheim outside the current study. Prof Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic.

Acknowledgements: Dr Rubio acknowledges NIH grant support (MHK23187300). Prof Howes acknowledges Medical Research Council-UK (no. MC_A656_5QD30_2135), Maudsley Charity (no. 666), and Wellcome Trust (no. 094849/Z/10/Z) grants and the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London.

Table 1: Meta-analysis mean duration of untreated psychosis (in weeks)

Group, subgroup	**No. of Studies**	**Sample size**	**DUP (in weeks)**			**Z score**	**P**		**Test for heterogeneity**			**Prediction interval**
			Mean	**95%CI**				**Q**	**I^2**	**Tau^2**	**P**	
Overall	**283**	**41,320**	**42.6**	**40.6**	**44.6**	**41.4**	**<0.001**	**12713.3**	**97.8**	**229.2**	**<0.001**	**12.1-73.1**
Africa	11	1,508	70.0	51.6	88.4	7.5	<0.001	237.7	95.8	219.2	<0.001	8.0-132.0
Asia	73	12,223	48.8	43.8	53.9	18.9	<0.001	4042.9	98.2	407.8	<0.001	6.9-90.7
North America	36	5,838	48.7	43.0	54.4	16.7	<0.001	992.5	96.5	832.8	<0.001	37.9-59.5
Europe	145	19,389	38.6	36.0	41.3	28.4	<0.001	7085.5	98.0	205.2	<0.001	10.3-66.9
South America	11	1,159	34.9	23.0	46.9	5.7	<0.001	89.7	94.4	100.4	<0.001	2.1-67.7
Australia	6	1,203	28.0	20.9	35.0	7.7	<0.001	83.9	88.1	94.4	<0.001	2.4-53.6

DUP: duration of untreated psychosis.

Table 2: Meta-analysis median duration of untreated psychosis (weeks)

Group, subgroup	**No. of Studies**	**Sample size**	**DUP in weeks**			**Range**
			Median	**IQR**		
Overall*	**206**	**37,215**	**14**	**8.8**	**28.0**	**0.6-110**
Africa	10	1,211	22.5	6.0	47.7	6-110
North America	37	7,390	20.8	9.1	35	0.6-52.1
Asia	43	8,689	17.1	12	28.9	1.7-52
Europe	102	16,500	12	8.2	27	0.7-104
South America	6	1,055	10	8.7	14	4.0-28
Australia	8	2,370	8	6.0	13	4.3-40.8

DUP: duration of untreated psychosis; IQR: Interquartile range.

*Between group heterogeneity was observed (H=9.5, p=0.049)

Table 3: Meta-regression analyses

	No. of Studies	β Coefficient	SE	95%CI		Z-Value	P value
% Affective psychosis	235	-0.130	0.119	-0.362	0.103	-1.09	0.275
Mean age	**266**	**0.836**	**0.250**	**0.346**	**1.325**	**3.35**	**<0.001**
% males	274	-0.051	0.029	-0.108	0.0067	-1.73	0.083
Sample size	280	0.051	0.004	-0.004	0.014	1.13	0.260
Year of publication	**280**	**-0.404**	**0.195**	**-0.786**	**-0.022**	**-2.07**	**0.038**
% White race	**64**	**-0.232**	**0.055**	**-0.339**	**-0.125**	**-4.26**	**<0.001**
% Single	29	-0.006	0.216	-0.430	0.417	-0.03	0.977
% Married	24	-0.0011	0.360	-0.706	0.704	0.00	0.997
% Living Alone	21	-3.296	1.807	-6.827	0.256	-1.82	0.069
Quality of the study	280	1.211	0.754	-0.267	2.689	1.610	0.108

REFERENCES

Ajnakina O, Morgan C, Gayer-Anderson C, Oduola S, Bourque F, Bramley S, . . . David AS (2017) Only a small proportion of patients with first episode psychosis come via prodromal services: a retrospective survey of a large UK mental health programme. *BMC Psychiatry* **17**(1)**,** 308. https://doi.org/10.1186/s12888-017-1468-y.

Anderson KK, Flora N, Ferrari M, Tuck A, Archie S, Kidd S, . . . Team AP (2015) Pathways to First-Episode Care for Psychosis in African-, Caribbean-, and European-Origin Groups in Ontario. *Canadian Journal of Psychiatry* **60**(5)**,** 223-231. https://doi.org/10.1177/070674371506000504.

Beiser M, Erickson D, Fleming JA and Iacono WG (1993) Establishing the onset of psychotic illness. *American Journal of Psychiatry* **150**(9)**,** 1349-1354. https://doi.org/10.1176/ajp.150.9.1349.

Bertolote J and McGorry P (2005) Early intervention and recovery for young people with early psychosis: consensus statement. *British Journal of Psychiatry Suppl* **48,** s116-119. https://doi.org/10.1192/bjp.187.48.s116.

Birnbaum ML, Rizvi AF, Confino J, Correll CU and Kane JM (2017) Role of social media and the Internet in pathways to care for adolescents and young adults with psychotic disorders and non-psychotic mood disorders. *Early Intervention in Psychiatry* **11**(4)**,** 290-295. https://doi.org/10.1111/eip.12237.

Birnbaum ML, Rizvi AF, Faber K, Addington J, Correll CU, Gerber C, . . . Kane JM (2018) Digital Trajectories to Care in First-Episode Psychosis. *Psychiatric Servervices* **69**(12)**,** 1259-1263. https://doi.org/10.1176/appi.ps.201800180.

Boonstra N, Klaassen R, Sytema S, Marshall M, De Haan L, Wunderink L, . . . Wiersma D (2012) Duration of untreated psychosis and negative symptoms--a systematic review and meta-analysis of individual patient data. *Schizophrenia Research* **142**(1-3)**,** 12-19. https://doi.org/10.1016/j.schres.2012.08.017.

Borenstein M, Hedges L, Higgins J and Rothstein H (2013) Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ.

Casey D, Brown L, Gajwani R, Islam Z, Jasani R, Parsons H, . . . Singh SP (2016) Predictors of engagement in first-episode psychosis. *Schizophrenia Research* **175**(1-3)**,** 204-208. https://doi.org/10.1016/j.schres.2016.04.030.

Chan SKW, Chan SWY, Pang HH, Yan KK, Hui CLM, Chang WC, . . . Chen EYH (2018) Association of an Early Intervention Service for Psychosis With Suicide Rate Among Patients With First-Episode Schizophrenia-Spectrum Disorders. *JAMA Psychiatry* **75**(5)**,** 458-464. https://doi.org/10.1001/jamapsychiatry.2018.0185.

Compton M, Carter T, Bergner E, Franz L, Stewart T, Trotman H, . . . McGorry P (2007) Defining, operationalizing and measuring the duration of untreated psychosis: advances, limitations and future directions. *Early Intervention in Psychiatry* **1,** 236-250.

Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, . . . Kane JM (2018a) Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis A Systematic Review, Meta-analysis, and Meta-regression. *JAMA Psychiatry* **75**(6)**,** 555-565. https://doi.org/10.1001/jamapsychiatry.2018.0623.

Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, . . . Kane JM (2018b) Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. *JAMA Psychiatry* **75**(6)**,** 555-565. https://doi.org/10.1001/jamapsychiatry.2018.0623.

Cullberg J, Levander S, Holmqvist R, Mattsson M and Wieselgren IM (2002) One-year outcome in first episode psychosis patients in the Swedish Parachute project. *Acta Psychiatrica Scandinavica* **106**(4)**,** 276-285. https://doi.org/10.1034/j.1600-0447.2002.02376.x.

Cullberg J, Mattsson M, Levander S, Holmqvist R, Tomsmark L, Elingfors C, . . . Wieselgren IM (2006) Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish 'Parachute Project' and Two Comparison Groups. *Acta Psychiatrica Scandinavica* **114**(4)**,** 274-281. https://doi.org/10.1111/j.1600-0447.2006.00788.x.

Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, . . . Thomas J (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic

Reviews of Interventions. *Cochrane Database of Systematic Reivews* **10,** ED000142. https://doi.org/10.1002/14651858.ED000142.
DerSimonian R and Laird N (1986) Meta-analysis in clinical trials. *Control Clinical Trials* **7**(3)**,** 177-188.
Dixon LB, Goldman HH, Srihari VH and Kane JM (2018) Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative. *Annual Review of Clinical Psychology* **14,** 237-258. https://doi.org/10.1146/annurev-clinpsy-050817-084934.
Egger M, Davey Smith G, Schneider M and Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* **315**(7109)**,** 629-634. https://doi.org/10.1136/bmj.315.7109.629.
Filia K, Menssink J, Gao CX, Rickwood D, Hamilton M, Hetrick SE, . . . Cotton SM (2022) Social inclusion, intersectionality, and profiles of vulnerable groups of young people seeking mental health support. *Social Psychiatry and Psychiatric Epidemiology* **57**(2)**,** 245-254. https://doi.org/10.1007/s00127-021-02123-8.
Fusar-Poli P, McGorry PD and Kane JM (2017) Improving outcomes of first-episode psychosis: an overview. *World Psychiatry* **16**(3)**,** 251-265. https://doi.org/10.1002/wps.20446.
Fusar-Poli P, Rutigliano G, Stahl D, Davies C, Bonoldi I, Reilly T, . . . McGuire P (2017) Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis. *JAMA Psychiatry* **74**(5)**,** 493-500. https://doi.org/10.1001/jamapsychiatry.2017.0284.
Fusar-Poli P, Salazar de Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, . . . Arango C (2020) Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. *JAMA Psychiatry*. https://doi.org/10.1001/jamapsychiatry.2019.4779.
Fusar-Poli P, Sullivan SA, Shah JL and Uhlhaas PJ (2019) Improving the Detection of Individuals at Clinical Risk for Psychosis in the Community, Primary and Secondary Care: An Integrated Evidence-Based Approach. *Frontiers in Psychiatry* **10**. https://doi.org/10.3389/fpsyt.2019.00774.
Golay P, Alameda L, Baumann P, Elowe J, Progin P, Polari A, . . . Conus P (2016) Duration of untreated psychosis: Impact of the definition of treatment onset on its predictive value over three years of treatment. *Journal of Psychiatric Research* **77,** 15-21. https://doi.org/10.1016/j.jpsychires.2016.02.017.
Grawe RW, Falloon IR, Widen JH and Skogvoll E (2006) Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study. *Acta Psychiatrica Scandinavica* **114**(5)**,** 328-336. https://doi.org/10.1111/j.1600-0447.2006.00799.x.
Guinart D, Kane JM and Correll CU (2019) Is Transcultural Psychiatry Possible? *JAMA* **322**(22)**,** 2167-2168. https://doi.org/10.1001/jama.2019.17331.
Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, . . . van der Heiden W (1992) IRAOS: an instrument for the assessment of onset and early course of schizophrenia. *Schizophrenia Research* **6**(3)**,** 209-223. https://doi.org/10.1016/0920-9964(92)90004-o.
Hegelstad WT, Larsen TK, Auestad B, Evensen J, Haahr U, Joa I, . . . McGlashan T (2012) Long-Term Follow-Up of the TIPS Early Detection in Psychosis Study: Effects on 10-Year Outcome. *American Journal of Psychiatry* **169**(4)**,** 374-380. https://doi.org/10.1176/appi.ajp.2011.11030459.
Howes O, Whitehurst T, Shatalina E, Townsend L, Onwordi E, TL. AM, . . . Osugo M (2021) The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. *World Psychiatry* **20,** 75-95.
Joa I, Johannessen JO, Auestad B, Friis S, McGlashan T, Melle I, . . . Larsen TK (2008) The key to reducing duration of untreated first psychosis: Information campaigns. *Schizophrenia Bulletin* **34**(3)**,** 466-472. https://doi.org/10.1093/schbul/sbm095.
Johannessen JO, McGlashan TH, Larsen TK, Horneland M, Joa I, Mardal S, . . . Vaglum P (2001) Early detection strategies for untreated first-episode psychosis. *Schizophrenia Research* **51**(1)**,** 39-46. https://doi.org/10.1016/s0920-9964(01)00237-7.
Johnstone EC, Crow TJ, Johnson AL and MacMillan JF (1986) The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. *British Journal of Psychiatry* **148,** 115-120. https://doi.org/10.1192/bjp.148.2.115.
Jonas KG, Fochtmann LJ, Perlman G, Tian Y, Kane JM, Bromet EJ, . . . Kotov R (2020) Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in

Schizophrenia. *American Journal of Psychiatry* **177**(4)**,** 327-334. https://doi.org/10.1176/appi.ajp.2019.19030324.
Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, . . . Heinssen RK (2016) Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. *American Journal of Psychiatry* **173**(4)**,** 362-372. https://doi.org/10.1176/appi.ajp.2015.15050632.
Kirkbride JB, Errazuriz A, Croudace TJ, Morgan C, Jackson D, Boydell J, . . . Jones PB (2012) Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. *PLoS One* **7**(3)**,** e31660. https://doi.org/10.1371/journal.pone.0031660.
Koplan JP, Bond TC, Merson MH, Reddy KS, Rodriguez MH, Sewankambo NK, . . . Board CoUfGHE (2009) Towards a common definition of global health. *Lancet* **373**(9679)**,** 1993-1995. https://doi.org/10.1016/S0140-6736(09)60332-9.
Large M, Sharma S, Compton MT, Slade T and Nielssen O (2011) Cannabis use and earlier onset of psychosis: a systematic meta-analysis. *Archives of General Psychiatry* **68**(6)**,** 555-561. https://doi.org/10.1001/archgenpsychiatry.2011.5.
Lieberman JA, Small SA and Girgis RR (2019) Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality. *American Journal of Psychiatry* **176**(10)**,** 794-810. https://doi.org/10.1176/appi.ajp.2019.19080865.
Lipsey M and Wilson D (2000) Practical Meta-analysis. In. Thousand Oaks, CA: Sage Publications.
Lloyd-Evans B, Crosby M, Stockton S, Pilling S, Hobbs L, Hinton M, . . . Johnson S (2011) Initiatives to shorten duration of untreated psychosis: systematic review. *British Journal of Psychiatry* **198**(4)**,** 256-263. https://doi.org/10.1192/bjp.bp.109.075622.
Lloyd-Evans B, Sweeney A, Hinton M, Morant N, Pilling S, Leibowitz J, . . . Johnson S (2015) Evaluation of a community awareness programme to reduce delays in referrals to early intervention services and enhance early detection of psychosis. *BMC Psychiatry* **15**. https://doi.org/10.1186/s12888-015-0485-y.
Lynch S, McFarlane WR, Joly B, Adelsheim S, Auther A, Cornblatt BA, . . . Downing D (2016) Early Detection, Intervention and Prevention of Psychosis Program: Community Outreach and Early Identification at Six US Sites. *Psychiatric Services* **67**(5)**,** 510-516. https://doi.org/10.1176/appi.ps.201300236.
Malla A and McGorry P (2019) Early Intervention in Psychosis in Young People: A Population and Public Health Perspective. *American Journal of Public Health* **109**(S3)**,** S181-S184. https://doi.org/10.2105/AJPH.2019.305018.
Malla A, Norman R, Schmitz N, Manchanda R, Béchard-Evans L, Takhar J, . . . Haricharan R (2006) Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. *Psychological Medicine* **36**(5)**,** 649-658. https://doi.org/10.1017/S0033291706007379.
Malla A, Roy MA, Abdel-Baki A, Conus P and McGorry P (2021) [Early Intervention for Psychosis from Past to Future: Overcoming Implementation Challenges to Maximize its Impact?]. *Sante Mentale Quebec* **46**(2)**,** 391-415.
Marchira CR, Supriyanto I, Subandi, Soewadi and Good BJ (2016) The association between duration of untreated psychosis in first psychotic episode patients and help seeking behaviors in Jogjakarta, Indonesia. *Internacional Journal of Culture and Mental Health* **9**(2)**,** 120-126. https://doi.org/10.1080/17542863.2015.1103276.
Melle I, Johannessen JO, Friis S, Haahr U, Joa I, Larsen TK, . . . McGlashan T (2010) Course and Predictors of Suicidality Over the First Two Years of Treatment in First-Episode Schizophrenia Spectrum Psychosis. *Archives of Suicide Research* **14**(2)**,** 158-170. https://doi.org/10.1080/13811111003704787.
Mihalopoulos C, Harris M, Henry L, Harrigan S and McGorry P (2009) Is Early Intervention in Psychosis Cost-Effective Over the Long Term? *Schizophrenia Bulletin* **35**(5)**,** 909-918. https://doi.org/10.1093/schbul/sbp054.
Mikton C, de la Fuente-Núñez V, Officer A and Krug E (2021) Ageism: a social determinant of health that has come of age. *Lancet* **397**(10282)**,** 1333-1334. https://doi.org/10.1016/S0140-6736(21)00524-9.

Moher D, Liberati A, Tetzlaff J, Altman DG and Group. P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Journal of Clinical Epidemiology* **62,** 1006-1012.

NHS-England The National Collaborating Centre for Mental Health and the National Institute for Health and Care Excellence (2016) Implementing the Early Intervention in Psychosis Access and Waiting Time Standard: Guidance. PR1954.

Nyaga V, Arbyn M and Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. *Archives of Public Health.* **72,** 39. https://doi.org/10.1186/ 2049-3258-72-39.

Oliver D, Davies C, Crossland G, Lim S, Gifford G, McGuire P, . . . Fusar-Poli P (2018a) Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies. *Schizophrenia Bulletin* **44**(6)**,** 1362-1372. https://doi.org/10.1093/schbul/sbx166.

Oliver D, Davies C, Crossland G, Lim S, Gifford G, McGuire P, . . . Fusar-Poli P (2018b) Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies. *Schizophrenia Bulletin* **44**(6)**,** 1362-1372. https://doi.org/10.1093/schbul/sbx166.

Patel V and Prince M (2010) Global mental health: a new global health field comes of age. *JAMA* **303**(19)**,** 1976-1977. https://doi.org/10.1001/jama.2010.616.

Pearson MR (2019) A meta-analytic investigation of the associations between cannabis use and cannabis-related negative consequences. *Psychology of Addictive Behaviors* **33**(3)**,** 190-196. https://doi.org/10.1037/adb0000452.

Penttila M, Jaaskelainen E, Hirvonen N, Isohanni M and Miettunen J (2014) Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. *British Journal of Psychiatry* **205**(2)**,** 88-94. https://doi.org/10.1192/bjp.bp.113.127753.

Perkins DO, Gu H, Boteva K and Lieberman JA (2005) Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. *American Journal of Psychiatry* **162**(10)**,** 1785-1804. https://doi.org/10.1176/appi.ajp.162.10.1785.

Polari A, Lavoie S, Sarrasin P, Pellanda V, Cotton S and Conus P (2011) Duration of untreated psychosis: a proposition regarding treatment definition. *Early Intervention in Psychiatry* **5**(4)**,** 301-308. https://doi.org/10.1111/j.1751-7893.2011.00308.x.

Qiu Y, Li L, Gan Z, Wang J, Zheng L, Zhao J, . . . Wei Q (2019) Factors related to duration of untreated psychosis of first episode schizophrenia spectrum disorder. *Early Intervention in Psychiatry* **13**(3)**,** 555-561. https://doi.org/10.1111/eip.12519.

Qureshi O, Endale T, Ryan G, Miguel-Esponda G, Iyer SN, Eaton J, . . . Murphy J (2021) Barriers and drivers to service delivery in global mental health projects. *International Journal of Mental Health Systems* **15**(1)**,** 14. https://doi.org/10.1186/s13033-020-00427-x.

Rice SM, Purcell R and McGorry PD (2018) Adolescent and Young Adult Male Mental Health: Transforming System Failures Into Proactive Models of Engagement. *Journal of Adolescent Health* **62**(3S)**,** S9-S17. https://doi.org/10.1016/j.jadohealth.2017.07.024.

Rickwood D, Paraskakis M, Quin D, Hobbs N, Ryall V, Trethowan J, . . . McGorry P (2019) Australia's innovation in youth mental health care: The headspace centre model. *Early Intervention in Psychiatry* **13**(1)**,** 159-166. https://doi.org/10.1111/eip.12740.

Rizos EN, Michalopoulou PG, Siafakas N, Stefanis N, Douzenis A, Rontos I, . . . Lykouras L (2010) Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia. *Neuropsychobiology* **62**(2)**,** 87-90. https://doi.org/10.1159/000315438.

Salazar de Pablo G, De Micheli A, Nieman DH, Correll CU, Kessing LV, Pfennig A, . . . Fusar-Poli P (2020) Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. *European Neuropsychopharmacology* **41,** 28-39. https://doi.org/10.1016/j.euroneuro.2020.10.007.

Salazar de Pablo G, Estradé A, Cutroni M, Andlauer O and Fusar-Poli P (2021) Establishing a clinical service to prevent psychosis: What, how and when? Systematic review. *Translational Psychiatry* **11**(1)**,** 43. https://doi.org/10.1038/s41398-020-01165-x.

Singh SP, Cooper JE, Fisher HL, Tarrant CJ, Lloyd T, Banjo J, . . . Jones P (2005) Determining the chronology and components of psychosis onset: The Nottingham Onset Schedule (NOS). *Schizophrenia Research* **80**(1)**,** 117-130. https://doi.org/10.1016/j.schres.2005.04.018.

Snodgrass JG, Lacy MG and Upadhyay C (2017) "Developing culturally sensitive affect scales for global mental health research and practice: Emotional balance, not named syndromes, in Indian Adivasi subjective well-being". *Social Science & Medicine* **187,** 174-183. https://doi.org/10.1016/j.socscimed.2017.06.037.

Sommer IE, Tiihonen J, van Mourik A, Tanskanen A and Taipale H (2020) The clinical course of schizophrenia in women and men-a nation-wide cohort study. *NPJ Schizophrenia* **6**(1)**,** 12. https://doi.org/10.1038/s41537-020-0102-z.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, . . . Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* **283**(15)**,** 2008-2012. https://doi.org/10.1001/jama.283.15.2008.

Tiffin PA and Hudson S (2007) An Early Intervention in Psychosis Service for adolescents. *Early Intervention in Psychiatry* **1**(2)**,** 212-218. https://doi.org/10.1111/j.1751-7893.2007.00024.x.

Wells G, Shea B, O Connell DL, Peterson J, Welch, Losos M, . . . Petersen J (2014) The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Medicine.

Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, . . . Buckby J (2005) Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. *Australian & New Zealand Journal of Psychiatry* **39**(11-12)**,** 964-971. https://doi.org/10.1080/j.1440-1614.2005.01714.x.